Pablo Lubroth

Automata was founded with a clear aim: to unlock human potential with automation. Through our collaboration with some of the world’s leading pathology labs, we’ve developed the most comprehensive lab automation platform on the market. By simplifying environments and empowering people, Automata enables labs to scale with precision and creates new opportunities for scientists to accelerate innovation.

Basecamp Research is an AI company dedicated to solving the most pressing challenges in the life sciences by exploring beyond known biology. The company discovers and designs proteins with artificial intelligence trained on its proprietary knowledge graph of nature, the largest and most diverse of its kind, to design biological solutions for pharma, food and industrial applications. Understanding the full genetic, evolutionary, and environmental context of each protein allows Basecamp Research to design tailored proteins for specific applications without the need for expensive and time-consuming directed evolution campaigns. Were a team of explorers, scientists and policy experts driven by our ambition to protect and learn from natures diversity, whilst delivering life-changing breakthroughs to those who need them most. – BCR

Pheiron is an AI research lab working towards a future of deterministic drug development. We are solving the hardest problem in drug development: anticipating what biology will work in humans. We are build causal foundation models of human biology to algorithmically underwrite biology risk, identify next-generation opportunities and pick winning mechanisms.

Amber Bio is a biotechnology company pioneering new gene editing modalities using multi-kilobase edits to reach previously undruggable patient populations. The current paradigm in genetic medicine relies on developing independent therapies for each separate mutation in the patient population. Founded by pioneers in the CRISPR field from leading institutions for gene editing research, the company is developing a first-of-its-kind RNA writing platform capable of editing thousands of diverse mutations across patients with a single product.

Building software to let you track your science across teams and tools: collaborate on projects, plan around compounds, candidates, or samples, and manage workflows, all in one spot.

Kernal creates mRNA therapies to cure severe diseases including cancer. Our mRNA therapies instruct specific cells on how to make their own drugs. With roots at MIT, Harvard and Big Pharma, our team previously built a successful Biotech company and has deep expertise in mRNA space.

At Enveda, we are systematically translating molecules found in medicinal plants into new drugs for challenging diseases. Our platform harnesses natures complexity with the help of cutting-edge advancements in knowledge graphs, machine learning, and metabolomics.

Waypoint Bio is a VC-backed biotech startup building the next generation of cell therapies for solid tumors.

An estimated 85% of the ~3 billion base pairs in the human genome is transcribed into RNA, but only ~1.5% of these code for proteins. While the chemical properties of protein binders are increasingly understood and interrogated, the field of RNA-targeted drugs is relatively new and the properties of small molecules that drive specific and selective targeting of RNA, and associated assays, are yet to be developed. At Serna Bio [previously Ladder Therapeutics] we are using an AI enabled, data-first approach to write the rules that define RNA-small molecule interactions. Our Discovery Platform powers our first-in-class small molecule programs targeted at classically undruggable proteins and non-coding RNA targets, targeting both human and non-human biology.

Hummingbird Ventures is an agile investor in entrepreneurial genius. We value emotional intelligence as much as data, growing internal culture as much as growing revenue, and forming strong, personal bonds with founders. Often the first institutional investor, we’ve helped start-ups scale from zero to category-defining multi-billion dollar businesses across 3 continents. We work best with outsiders who challenge industry boundaries and conventions, transforming tiny miracles into impactful companies. Hummingbird Ventures teamed up with transformative companies, including Deliveroo, Showpad, Kraken, Peak Games, Amplidata, Gram Games, Shutl, Merlin, Billiontoone and many others.

NanoSyrinx is a cutting-edge synthetic biology company creating the next generation of targeted drug delivery systems to address challenges in the biologic delivery sector.

MicrofluidX presents the Cyto Engine, a unified bioreactor and data platform for cell and gene therapy research, development, and manufacturing

Atelerix has a transformative technology for the storage and transport of viable cells at room temperature, overcoming the barriers and limitations presented by the current need for cryo-shipping. We use alginate hydrogels to encapsulate biological products, protecting them from biochemical and physical damage during storage and shipment. We can hold cells and tissues at room temperature for up to two weeks, effectively placing them into a state of hibernation - just like the African pygmy hedgehog, genus Atelerix!

GLIALIGN LIMITED is a new tissue engineering/ regenerative medicine company based in University College London School of Pharmacy, Brunswick Square, London WC1N 1AX. The Companys focus is on novel cells/materials constructs for neural tissue repair. Glialign is funded by the UCL Tech Fund, UK Innovation and Science Seed Fund and Innovate UK

At Cytox our mission is enable everyone to know their personal risk for Alzheimer's disease. Alzheimer’s disease today affects over 46 million people globally and this is projected to reach 75 million by 2030 and over 131 million people by 2050. Cytox has developed genoSCORE™ technology that assesses over 100,000 bits of DNA to compute an individual's genetic risk of developing Alzheimer's disease as a single risk score. This technology forms the basis of a Polygenic Risk Score test for Alzheimer's disease that is available in the US and the UK. In the US, the Alzheimer’s Risk Test is available from Sampled SMART Labs (www.Sampled.com), who developed it based on genoSCORE™ technology supplied by Cytox. In the UK, information about the test can be found at www.genoscore-lab.com. The benefits of genetic testing include understanding the importance of taking action to reduce the chance of developing Alzheimer's disease, because AD risk isn’t just about genetics. Lifestyle and environmental factors play a significant role, too. One of the advantages of a personal risk score is that it can provide the motivation to make lifestyle adjustments, although being prepared for the result is an essential requirement for anyone who goes down the testing route.

Interlagos is a technology investment company based in Los Angeles, California focused on applied science and manufacturing. contact@interlagos.com

Automata was founded with a clear aim: to unlock human potential with automation. Through our collaboration with some of the world’s leading pathology labs, we’ve developed the most comprehensive lab automation platform on the market. By simplifying environments and empowering people, Automata enables labs to scale with precision and creates new opportunities for scientists to accelerate innovation.

Basecamp Research is an AI company dedicated to solving the most pressing challenges in the life sciences by exploring beyond known biology. The company discovers and designs proteins with artificial intelligence trained on its proprietary knowledge graph of nature, the largest and most diverse of its kind, to design biological solutions for pharma, food and industrial applications. Understanding the full genetic, evolutionary, and environmental context of each protein allows Basecamp Research to design tailored proteins for specific applications without the need for expensive and time-consuming directed evolution campaigns. Were a team of explorers, scientists and policy experts driven by our ambition to protect and learn from natures diversity, whilst delivering life-changing breakthroughs to those who need them most. – BCR

Pheiron is an AI research lab working towards a future of deterministic drug development. We are solving the hardest problem in drug development: anticipating what biology will work in humans. We are build causal foundation models of human biology to algorithmically underwrite biology risk, identify next-generation opportunities and pick winning mechanisms.

Amber Bio is a biotechnology company pioneering new gene editing modalities using multi-kilobase edits to reach previously undruggable patient populations. The current paradigm in genetic medicine relies on developing independent therapies for each separate mutation in the patient population. Founded by pioneers in the CRISPR field from leading institutions for gene editing research, the company is developing a first-of-its-kind RNA writing platform capable of editing thousands of diverse mutations across patients with a single product.